Emma von Witting
Royal Institute of Technology
Conjugated systemBiophysicsProtein GMolecular imagingClearanceProtein engineeringAntibodySmall moleculeSerum albuminMonomerMolecular recognitionCovalent bondChemistryPhage displayConjugateAdverse effectIn vivoBinding domainAlbuminAngiogeninToxinLungBiodistributionContrast (music)DimerDOTAKidneyLabellingLinkerAffinity maturationSpect imagingNuclear medicineRadionuclide imagingRadionuclide therapyHer2 expressionComparative evaluationNovel proteinEffective treatmentTumour targetingBreast cancerScaffold proteinHistopathologyBiochemistryComputational biologyMedicineSelection (genetic algorithm)Ternary complexScaffoldCell biology
10Publications
4H-index
30Citations
Publications 10
Newest
#1Olga Bragina (RAS: Russian Academy of Sciences)H-Index: 4
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 16 authors...
Radionuclide molecular imaging of human epidermal growth factor (HER2) expression may be helpful to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. ADAPTs (albumin-binding domain derived affinity proteins) are a new type of small (46-59 amino acids) proteins useful as probes for molecular imaging. The aim of this first-in-human study was to evaluate biodistribution, dosimetry, and safety of the HER2-specific 99mTc-ADAPT6. METHODS: Twenty-nine patients with prim...
8 CitationsSource
#1Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Albumin-binding fusion partners are frequently used as a means for the in vivo half-life extension of small therapeutic molecules that would normally be cleared very rapidly from circulation. However, in applications where small size is key, fusion to an additional molecule can be disadvantageous. Albumin-derived affinity proteins (ADAPTs) are a new type of scaffold proteins based on one of the albumin-binding domains of streptococcal protein G, with engineered binding specificities against nume...
Source
#1Javad Garousi (Uppsala University)H-Index: 13
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract Molecular recognition in targeted therapeutics is typically based on immunoglobulins. Development of engineered scaffold proteins (ESPs) has provided additional opportunities for the development of targeted therapies. ESPs offer inexpensive production in prokaryotic hosts, high stability and convenient approaches to modify their biodistribution. In this study, we demonstrated successful modification of the biodistribution of an ESP known as ADAPT (Albumin-binding domain Derived Affinity...
1 CitationsSource
#1Emma von WittingH-Index: 4
#2Sarah LindboH-Index: 8
Last. Sophia HoberH-Index: 41
view all 11 authors...
Albumin-binding fusion partners are frequently used as a means for the in vivo half-life extension of small therapeutic molecules that would normally be cleared very rapidly from circulation. Howev ...
#1Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 10 authors...
Abstract Radionuclide molecular imaging is a promising tool that becomes increasingly important as targeted cancer therapies are developed. To ensure an effective treatment, a molecular stratification of the cancer is a necessity. To accomplish this, visualization of cancer associated molecular abnormalities in vivo by molecular imaging is the method of choice. ADAPTs, a novel type of small protein scaffold, have been utilized to select and develop high affinity binders to different proteinaceou...
7 CitationsSource
First-in-humans Evaluation of [Tc-99m]-ADAPT6, a Novel Scaffold Protein for Visualizationof HER2 Expression
#1Javad Garousi (Uppsala University)H-Index: 13
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have demonstrated very promising features as vectors for radionuclide tumour targeting. Radionuclide imaging of human epidermal growth factor 2 (HER2) expression in vivo might be used for stratification of patients for HER2-targeting therapies. ADAPT6, which specifically binds to HER2, has earlier been shown to have very promising features for in vivo targeting of HER2 expressing tumours. In this study we tested the...
11 CitationsSource
Selection of the optimal macrocyclic chelators for labelling with In-111 and Ga-68 improves contrast of HER2 imaging using engineered scaffold protein ADAPT6
Selection Of The Optimal Macrocyclic Chelators For Labelling With In-111 And Ga-68 Improves Contrast Of Her2 Imaging Using Engineered Scaffold Protein Adapt6
#1Sara KanjeH-Index: 6
#2Emma von WittingH-Index: 4
Last. Sophia HoberH-Index: 41
view all 5 authors...
Antibodies are widely used reagents for recognition in both clinic and research laboratories all over the world. For many applications, antibodies are labeled through conjugation to different reporter molecules or therapeutic agents. Traditionally, antibodies are covalently conjugated to reporter molecules via primary amines on lysines or thiols on cysteines. While efficient, such labeling is variable and nonstoichiometric and may affect an antibody’s binding to its target. Moreover, an emerging...
8 CitationsSource